DDInter425 DDInter782
Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma.
In April 2018, the U.S. Food and Drug Administration (FDA) and the Swiss company Helsinn approved the intravenous formulation of AKYNZEO® (NEPA, a fixed antiemetic combination of fosnetupitant, 235mg, and palonosetron, 0.25mg) as an alternative treatment option for patients experiencing chemotherapy-induced nausea and vomiting . Fosnetupitant is the pro-drug form of netupitant [FDA label]. Generally, 25% to 30% of patients with a diagnosis of cancer receive chemotherapy as a treatment modality and 70% to 80% of these patients undergoing chemotherapy treatment may experience nausea and vomiting as major side effects. Considered one of the most distressing side effects of chemotherapy, nausea and vomiting has an immense impact on the quality of life of patients receiving certain antineoplastic therapies .
Cobimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fostamatinib
Cobimetinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Aminoglutethimide
Cobimetinib {u} may lead to a major life threatening interaction when taken with {v} Mumps virus strain B level jeryl lynn live antigen
Cobimetinib {u} may lead to a major life threatening interaction when taken with {v} Imatinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide
Cobimetinib may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen
Cobimetinib may lead to a major life threatening interaction when taken with Imatinib